SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Black sunshine
Search This Board:
Last Post: 9/26/2016 6:54:28 PM - Followers: 149 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IDRA News: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Th... 07:30 AM
IDRA News: Idera Pharmaceuticals legt vielversprechende Daten zur laufenden klinischen Phase-I-Dosiseskalationsstudie von intratumoralem... 09/26/2016 07:36:03 PM
IDRA News: Idera Pharmaceuticals communique des données prometteuses concernant l'étude clinique de Phase I en cours à dose croissant... 09/26/2016 07:36:01 PM
IDRA News: Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125... 09/26/2016 07:00:14 AM
IDRA News: Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125... 09/26/2016 07:00:00 AM
News News Alert: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Th... 09/27/2016 07:30:00 AM
#2590   Currently testing the b/o resistance level to see Citrati 09/26/16 02:29:44 PM
#2589   Actually after listening to the conference call, I koman 09/26/16 02:19:35 PM
#2587   ... And back below my profit taking level... Cbdpotential 09/26/16 01:33:05 PM
#2586   Interesting to see the price labels versus present Citrati 09/26/16 10:28:08 AM
#2585   Yeehaw!!! Cbdpotential 09/26/16 10:26:39 AM
#2584   always smart to lock in profits. I dumped Randolph Duke 09/26/16 10:21:58 AM
#2583   Money management is a must with stocks and Citrati 09/26/16 10:17:34 AM
#2582   I took some profits before 3$ ... :-( Cbdpotential 09/26/16 10:13:53 AM
#2581   Boom! Cbdpotential 09/26/16 10:04:23 AM
#2580   The emphasis on today's PR is that these koman 09/26/16 09:52:51 AM
#2579   GREEN $IDRA Cbdpotential 09/26/16 08:29:56 AM
#2578   Idera Pharmaceuticals Reports Promising Data from Ongoing Phase Cbdpotential 09/26/16 08:06:16 AM
#2577   If you like the KISS method, you may Citrati 09/25/16 12:01:03 PM
#2576   I dumped a few to lock in profits- Randolph Duke 09/23/16 05:17:45 PM
#2575   Have a much smaller core here now 2.8 Have a Cbdpotential 09/23/16 01:28:42 PM
#2574   Ask at 4.45 lol sup jde313 09/22/16 11:27:57 PM
#2573   What an awesome day today. Citrati 09/22/16 09:17:23 PM
#2572   :-D Thanks for the analysis As always Cbdpotential 09/22/16 07:07:05 AM
#2571   * * $IDRA Video Chart 09-21-16 * * ClayTrader 09/21/16 04:54:02 PM
#2570   Wow Nice EOD recovery... Cbdpotential 09/21/16 03:20:43 PM
#2569   Very busy playing other stocks the last few rivervalley 09/21/16 10:15:38 AM
#2568   Thank you Woke up late and let a few Cbdpotential 09/21/16 10:04:19 AM
#2567   Congrats on Green Cbd. :-) Citrati 09/21/16 09:44:50 AM
#2566   Taking some profits today :-D Holding my core Good luck everyone Cbdpotential 09/21/16 09:36:02 AM
#2565   Looking forward to see what tomorrow brings. jde313 09/20/16 10:11:23 PM
#2564   2.89 ah Cbdpotential 09/20/16 05:37:50 PM
#2563   Clay Traders here. We must be about Moto260 09/20/16 05:37:21 PM
#2562   * * $IDRA Video Chart 09-20-16 * * ClayTrader 09/20/16 04:56:38 PM
#2561   ETF's? This is seeing a ton of volume Randolph Duke 09/20/16 04:18:03 PM
#2560   How awesome is closing within .03 of the HOD? Citrati 09/20/16 04:00:59 PM
#2559   Glad it was helpful. Citrati 09/20/16 03:32:03 PM
#2558   Thank you Citrati! I logged on to ask Seel 09/20/16 03:00:44 PM
#2557   Targets? Citrati 09/20/16 02:47:55 PM
#2556   Absolutely no way this is retail. Sure some Citrati 09/20/16 01:52:31 PM
#2555   It's beautiful! 8-) Cbdpotential 09/20/16 01:02:33 PM
#2554   Nice strong run in play. Haven't seen it Randolph Duke 09/20/16 12:31:27 PM
#2553   Cbd, that is a possibility. Citrati 09/20/16 10:48:18 AM
#2552   We might see a drop to test 2$ Jmho I Cbdpotential 09/20/16 09:38:02 AM
#2551   Roughly 6700 shares sold premarket at 2.47 to xdrt91 09/20/16 09:23:24 AM
#2550   :-) GREEN ! Under 2$'s were money ;-) Keep this momentum Cbdpotential 09/20/16 08:41:48 AM
#2549   :-D Go $IDRA go !!! GREEN :-D Cbdpotential 09/20/16 08:36:32 AM
#2548   PM bid 2.46 and no real vol to rivervalley 09/20/16 08:25:24 AM
#2547   :-D Green! Cbdpotential 09/19/16 12:24:32 PM
#2546   Nice Vol again this morning, looking good! rivervalley 09/19/16 10:12:35 AM
#2545   :-) :-) Citrati 09/19/16 10:05:10 AM
#2544   I must admit I know nothing about this Ilhabela777 09/18/16 11:29:27 PM
#2543   Big break through today with volume- very nice! Randolph Duke 09/16/16 06:21:50 PM
#2542   Todays volume supports your feeling. Higher than its Seel 09/16/16 01:19:57 PM
#2541   Just have that feeling... Looking forward to next week Cbdpotential 09/16/16 01:10:20 PM
#2540   Hope we can stay above the 2$ soil Cbdpotential 09/16/16 12:05:15 PM